People search Epitalon and MOTS-c together because both are sold under the same “longevity peptide” banner. The comparison matters precisely because that banner hides how different they are: same marketing category, different biology, different evidence, different FDA indication. The table above is the row-by-row breakdown. Below is what each row means.
Epitalon vs MOTS-c: the short version
Both are research peptides with preclinical evidence, no published human randomized controlled trial, and no approval in any major jurisdiction. Both sit on the agenda of the same FDA compounding meeting on July 23-24, 2026. The cleanest difference is not which is “better” but what each is for: Epitalon is studied around circadian and ageing biology, MOTS-c around metabolism. Treating them as interchangeable longevity options is the mistake.
Evidence: both preclinical, one with a trial
What is known about either comes from cell and animal studies. MOTS-c, a mitochondrial-derived peptide, has the more active pipeline: a recruiting Phase 2 trial in adults for insulin sensitivity. Epitalon, a pineal tetrapeptide, has no registered human trial. Neither has a published randomized controlled trial, the bar for “this works in people.” For how we weigh these tiers, see our how we grade evidence explainer, the full Epitalon evidence and regulatory record, and the MOTS-c evidence and regulatory record.
Different biology, same banner
Epitalon (Ala-Glu-Asp-Gly) is a synthetic pineal tetrapeptide studied for its effects on circadian signalling and markers of ageing. MOTS-c is a peptide encoded in mitochondrial DNA, studied as a regulator of metabolism, AMPK signalling and insulin sensitivity. They are not two routes to the same outcome; they are two molecules that happen to be marketed to the same audience. That is why a head-to-head on “which extends lifespan” has no sourced answer in 2026.
Regulation: the same July 2026 meeting
Both were removed from the FDA 503A “do not compound” list in April 2026, which did not make them compoundable. The Pharmacy Compounding Advisory Committee reviews MOTS-c on July 23 (evaluated indication: obesity and osteoporosis) and Epitalon on July 24 (evaluated indication: insomnia). We track the meeting in the July 2026 FDA peptide meeting, explained. Neither carries a marketing authorization in the European Union, and as non-approved substances both should be treated as prohibited under anti-doping rules.
So which one, if either?
There is no defensible “winner” because they are not competing for the same job. Both are unproven in humans; MOTS-c has a registered metabolic trial and a metabolic rationale, Epitalon has neither a trial nor a metabolic claim. If a guide ranks one above the other on longevity, it is ranking marketing, not data. Watch the July 2026 meeting for the next real change.
Research information only. Neither Epitalon nor MOTS-c is approved for human use. Talk to a licensed physician before considering any peptide.